Lead change of a HIF-2α antagonist guided by multiparameter optimization and utilization of an Olp→π*Ar interaction
作者:Paul M. Wehn、Song Yang、Jonas A. Grina、James P. Rizzi、Stephen T. Schlachter、Bin Wang、Rui Xu、Hanbiao Yang、Xinlin Du、Guangzhou Han、Keshi Wang、Robert M. Czerwinski、Emily L. Ged、Heli Huang、Megan M. Halfmann、Melissa A. Maddie、Emily R. Morton、Sarah R. Olive、Huiling Tan、Shanhai Xie、John A. Josey、Eli M. Wallace
DOI:10.1007/s00044-023-03088-w
日期:2023.7
(2) improved solubility, but with the compromise of reduced potency. In area (3), understanding the importance of an Olp→π*Ar interaction, as documented through a wealth of crystal structures and retrospective calculations, proved essential in guiding SAR and identifying the trifluoromethyl group as a suitable replacement of the sulfone. Only by combining these three strategies could inhibitors with
Disclosed herein are substituted indane derivatives useful as HIF-2α inhibitors. Pharmaceutical compositions comprising said indane derivatives and methods of using said indane derivatives for treating proliferative diseases, such as renal cell carcinoma and von Hippel-Lindau disease, and other conditions associated with HIF-2α activity are also disclosed.
本文公开了可用作 HIF-2α 抑制剂的取代茚满衍生物。还公开了包含所述茚满衍生物的药物组合物和使用所述茚满衍生物治疗增殖性疾病(如肾细胞癌和 von Hippel-Lindau 病)以及其他与 HIF-2α 活性有关的疾病的方法。
AROMATIC COMPOUNDS AND USES THEREOF
申请人:PELOTON THERAPEUTICS, INC.
公开号:US20180162807A1
公开(公告)日:2018-06-14
Aromatic entities that modulate HIF-2α activity, pharmaceutical compositions containing the aromatic entities, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2α activity are described herein.
[EN] AROMATIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS AROMATIQUES, LEURS ET UTILISATIONS
申请人:PELOTON THERAPEUTICS INC
公开号:WO2016144825A1
公开(公告)日:2016-09-15
Aromatic entities that modulate HIF-2α activity, pharmaceutical compositions containing the aromatic entities, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2α activity are described herein.